跳至主要内容
临床试验/NCT01503476
NCT01503476已完成4 期

RD-40 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance

Medtronic - MITG1 个研究点 分布在 1 个国家目标入组 170 人开始时间: 2012年2月最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
170
试验地点
1
主要终点
Percentage of data samples transmitted by the capsule and successfully received by the receiver (e.g. percent of missed samples and percent of corrupted samples)

研究概览

简要总结

Study Hypothesis:

This study is designed as an integral part of the development of new or improved features or components of the Bravo® pH Monitoring System and may serve verification and validation purposes The study population will include a group of healthy volunteers (Group A) and a group of symptomatic patients with known or suspected gastroesophageal reflux disease (Group B).

Group A: Healthy volunteers will not undergo invasive procedure. These volunteers may be asked to carry the capsule and\or Bravo Recorder. These procedures will serve to evaluate different technical matters such as human interface, ergonomic aspects and communication performances of the system Group B: Symptomatic patients will undergo invasive procedure, including Bravo capsule delivery, positioning and attachment. Confirmation of capsule attachment may be done by endoscopically.

These procedures will serve to evaluate overall system performance in actual clinical setup, for instance: Bravo Recorder performance including communication quality, human interface and similar, ergonomics of delivery device, pH Capsule performance, etc.

Subjects from both study groups as well as physician may be asked to provide feedback on the procedure and/or document their activities during the procedure.

详细描述

Up to a total of 220 subjects will participate in this study. The study will include two separate population groups. Group A of up to 170 healthy volunteers and Group B of up to 50 symptomatic patients with known or suspected gastro esophageal reflux disease.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject age ≥ 18 years old
  • Subject received an explanation about the nature of the study and agrees to provide written informed consent.
  • Group A (healthy volunteers) Only
  • Subject is an healthy volunteer
  • Group B (symptomatic patients) Only
  • The subject was referred for pH monitoring procedure to detect acid reflux for at least one of the following reasons:
  • Burning substernal chest pain (heartburn)
  • Regurgitation of food or stomach contents
  • Dysphagia
  • Epigastric pain
  • Non-erosive reflux disease (NERD)

排除标准

  • Group A and B-
  • Subject has a cardiac pacemaker or other implanted electromedical device.
  • Subject has any condition, which precludes compliance with study and/or device instructions.
  • Women who are either pregnant or nursing at the time of screening, or are of child-bearing potential and do not practice medically acceptable methods of contraception.
  • Subject suffers from life threatening conditions
  • Subject currently participating in another clinical study which may interfere with study objectives, per physician discretion
  • Additional exclusion criteria for Group B only
  • Subject has prior abdominal surgery other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator
  • Subject is schedule to undergo MRI examination within 30 days from pH monitoring procedure.
  • Subject has known bleeding diathesis, strictures, severe esophagitis, varices and or obstructions -

研究组 & 干预措施

Healthy volunteers

Experimental

healthy volunteers

干预措施: Bravo® pH Monitoring System (Device)

symptomatic patients

Experimental

symptomatic patients with known or suspected gastro esophageal reflux disease

干预措施: Bravo® pH Monitoring System (Device)

结局指标

主要结局

Percentage of data samples transmitted by the capsule and successfully received by the receiver (e.g. percent of missed samples and percent of corrupted samples)

时间窗: up to 96 hours

Percentage of data samples in healthy volunteers and patients transmitted by capsule and successfully received by the receiver (e.g. percent of missed samples and percent of corrupted samples)

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验